Search

Your search keyword '"Moore, R. D."' showing total 207 results
Start Over Author "Moore, R. D." Search Limiters Available in Library Collection
207 results on '"Moore, R. D."'

4. The Authors Reply

Author

Crane, H. M., Heckbert, S. R., Drozd, D. R., Budoff, M. J., Delaney, J. A. C., Rodriguez, C., Paramsothy, P., Lober, W. B., Burkholder, G., Willig, J. H., Mugavero, M. J., Mathews, W. C., Crane, P. K., Moore, R. D., Napravnik, S., Eron, J. J., Hunt, P., Geng, E., Hsue, P., Barnes, G. S., McReynolds, J., Peter, I., Grunfeld, C., Saag, M. S., and Kitahata, M. M.

Published
2014
Full Text
View/download PDF

5. Lessons Learned From the Design and Implementation of Myocardial Infarction Adjudication Tailored for HIV Clinical Cohorts

Author

Crane, H. M., Heckbert, S. R., Drozd, D. R., Budoff, M. J., Delaney, J. A. C., Rodriguez, C., Paramsothy, P., Lober, W. B., Burkholder, G., Willig, J. H., Mugavero, M. J., Mathews, W. C., Crane, P. K., Moore, R. D., Napravnik, S., Eron, J. J., Hunt, P., Geng, E., Hsue, P., Barnes, G. S., McReynolds, J., Peter, I., Grunfeld, C., Saag, M. S., and Kitahata, M. M.

Published
2014
Full Text
View/download PDF

8. Anemia risk factors among people living with HIV across the United States in the current treatment era: a clinical cohort study

Author

Harding, B. N., primary, Whitney, B. M., additional, Nance, R. M., additional, Ruderman, S. A., additional, Crane, H. M., additional, Burkholder, G., additional, Moore, R. D., additional, Mathews, W. C., additional, Eron, J. J., additional, Hunt, P. W., additional, Volberding, P., additional, Rodriguez, B., additional, Mayer, K. H., additional, Saag, M. S., additional, Kitahata, M. M., additional, Heckbert, S. R., additional, and Delaney, J. A. C., additional

Published
2020
Full Text
View/download PDF

9. ESTIMATING WINTER STREAMFLOW USING CONCEPTUAL STREAMFLOW MODEL

Author

Hamilton, A. S., Hutchinson, D. G., and Moore, R. D.

Subjects
Canada -- Environmental aspects, Hydrography -- Research, Streamflow -- Research, Winter -- Environmental aspects, Hydrology -- Research, Engineering models -- Usage, Engineering and manufacturing industries, Science and technology
Abstract

Ice-affected periods represent a significant portion of the annual hydrograph for most Canadian hydrometric stations. Because the stage-discharge relation is not reliable under ice-cover conditions, Water Survey of Canada subjectively interpolates winter streamflow from as few as two observations of discharge during the ice-covered season, which may last 6 months or longer. An alternative method of producing discharge estimates is proposed that uses a combination of conceptual and statistical hydrological modeling to overcome limitations in both the availability of data and our understanding of relevant processes. A conceptual hydrological model is tested to evaluate the utility of this approach for data-sparse regions. When model predictions were adjusted to fit two winter measurements, 79% of all verification measurements were within 20% of predicted estimates. There was a seasonal bias to the error distribution, with most measurements within the first 30 days after freeze-up being less than predicted and most measurements after April 1 being greater than predicted. These deviations probably result from hydraulic and hydrologic processes not represented within the model.

Published
2000

10. Comparison of Kaposi Sarcoma Risk in Human Immunodeficiency Virus-Positive Adults Across 5 Continents: A Multiregional Multicohort Study

Author

Rohner E., Butikofer L., Schmidlin K., Sengayi M., Maskew M., Giddy J., Garone D., Moore R. D., D'Souza G., Goedert J. J., Achenbach C., Gill M. J., Kitahata M. M., Patel P., Silverberg M. J., Castilho J., McGowan C., Chen Y. -M. A., Law M., Taylor N., Paparizos V., Bonnet F., Verbon A., Fatkenheuer G., Post F. A., Sabin C., Mocroft A., Le Moing V., Dronda F., Obel N., Grabar S., Spagnuolo V., Antinori A., Quiros-Roldan E., Mussini C., Miro J. M., Meyer L., Hasse B., Konopnicki D., Roca B., Barger D., Raben D., Clifford G. M., Franceschi S., Brockmeyer N., Chakraborty R., Egger M., Bohlius J., Judd A., Zangerle R., Touloumi G., Warszawski J., Dabis F., Krause M. M., Ghosn J., Leport C., Wittkop L., Reiss P., Wit F., Prins M., Bucher H., Gibb D., Del Amo J., Thorne C., Kirk O., Stephan C., Perez-Hoyos S., Hamouda O., Bartmeyer B., Chkhartishvili N., Noguera-Julian A., Monforte A. D., Prieto L., Conejo P. R., Soriano-Arandes A., Battegay M., Kouyos R., Tookey P., Casabona J., Castagna A., Konopnick D., Goetghebuer T., Sonnerborg A., Teira R., Garrido M., Haerry D., De Wit S., Costagliola D., D'Arminio-Monforte A., Chene G., Schwimmer C., Termote M., Campbell M., Frederiksen C. M., Friis-Moller N., Kjaer J., Brandt R. S., Berenguer J., Bouteloup V., Cozzi-Lepri A., Davies M. -A., Dorrucci M., Dunn D., Furrer H., Guiguet M., Lambotte O., Leroy V., Lodi S., Matheron S., Monge S., Nakagawa F., Paredes R., Phillips A., Puoti M., Schomaker M., Smit C., Sterne J., Thiebaut R., Torti C., Van Der Valk M., Tanser F., Vinikoor M., MacEte E., Wood R., Stinson K., Fatti G., Phiri S., Chimbetete C., Malisita K., Eley B., Fritz C., Hobbins M., Kamenova K., Fox M., Prozesky H., Technau K., Sawry S., Benson C. A., Bosch R. J., Kirk G. D., Boswell S., Mayer K. H., Grasso C., Hogg R. S., Harrigan P. R., Montaner J. S. G., Yip B., Zhu J., Salters K., Gabler K., Buchacz K., Brooks J. T., Gebo K. A., Carey J. T., Rodriguez B., Horberg M. A., Thorne J. E., Rabkin C., Margolick J. B., Jacobson L. P., Klein M. B., Rourke S. B., Rachlis A. R., Cupido P., Hunter-Mellado R. F., Mayor A. M., Deeks S. G., Martin J. N., Saag M. S., Mugavero M. J., Willig J., Eron J. J., Napravnik S., Crane H. M., Drozd D. R., Haas D., Rebeiro P., Turner M., Bebawy S., Rogers B., Justice A. C., Dubrow R., Fiellin D., Gange S. J., Anastos K., Althoff K. N., McKaig R. G., Freeman A. M., Lent C., Van Rompaey S. E., Morton L., McReynolds J., Lober W. B., Abraham A. G., Lau B., Zhang J., Jing J., Modur S., Wong C., Hogan B., Desir F., Liu B., You B., Cahn P., Cesar C., Fink V., Sued O., Dell'Isola E., Perez H., Valiente J., Yamamoto C., Grinsztejn B., Veloso V., Luz P., De Boni R., Wagner S. C., Friedman R., Moreira R., Pinto J., Ferreira F., Maia M., De Menezes Succi R. C., MacHado D. M., De Fatima Barbosa Gouvea A., Wolff M., Cortes C., Rodriguez M. F., Allendes G., Pape J. W., Rouzier V., Marcelin A., Perodin C., Luque M. T., Padgett D., Madero J. S., Ramirez B. C., Belaunzaran P., Vega Y. C., Gotuzzo E., Mejia F., Carriquiry G., McGowan C. C., Shepherd B. E., Sterling T., Jayathilake K., Person A. K., Rebeiro P. F., Giganti M., Duda S. N., Maruri F., Vansell H., Ly P. S., Khol V., Zhang F. J., Zhao H. X., Han N., Lee M. P., Li P. C. K., Lam W., Chan Y. T., Kumarasamy N., Saghayam S., Ezhilarasi C., Pujari S., Joshi K., Gaikwad S., Chitalikar A., Merati T. P., Wirawan D. N., Yuliana F., Yunihastuti E., Imran D., Widhani A., Tanuma J., Oka S., Nishijima T., Choi J. Y., Na S., Kim J. M., Sim B. L. H., Gani Y. M., David R., Kamarulzaman A., Syed Omar S. F., Ponnampalavanar S., Azwa I., Ditangco R., Uy E., Bantique R., Wong W. W., Ku W. W., Wu P. C., Ng O. T., Lim P. L., Lee L. S., Ohnmar P. S., Avihingsanon A., Gatechompol S., Phanuphak P., Phadungphon C., Kiertiburanakul S., Sungkanuparph S., Chumla L., Sanmeema N., Chaiwarith R., Sirisanthana T., Kotarathititum W., Praparattanapan J., Kantipong P., Kambua P., Ratanasuwan W., Sriondee R., Nguyen K. V., Bui H. V., Nguyen D. T. H., Nguyen D. T., Cuong D. D., An N. V., Luan N. T., Sohn A. H., Ross J. L., Petersen B., Cooper D. A., Law M. G., Jiamsakul A., Boettiger D. C., Ellis D., Bloch M., Agrawal S., Vincent T., Allen D., Smith D., Rankin A., Baker D., Templeton D. J., Jackson E., McCallum K., Ryder N., Sweeney G., Cooper D., Carr A., MacRae K., Hesse K., Finlayson R., Gupta S., Langton-Lockton J., Shakeshaft J., Brown K., Idle S., Arvela N., Varma R., Lu H., Couldwell D., Eswarappa S., Smith D. E., Furner V., Cabrera G., Fernando S., Cogle A., Lawrence C., Mulhall B., Boyd M., Petoumenos K., Puhr R., Huang R., Han A., Gunathilake M., Payne R., O'Sullivan M., Croydon A., Russell D., Cashman C., Roberts C., Sowden D., Taing K., Marshall P., Orth D., Youds D., Rowling D., Latch N., Warzywoda E., Dickson B., Donohue W., Moore R., Edwards S., Boyd S., Roth N. J., Lau H., Read T., Silvers J., Zeng W., Hoy J., Watson K., Bryant M., Price S., Woolley I., Giles M., Korman T., Williams J., Nolan D., Allen A., Guelfi G., Mills G., Wharry C., Raymond N., Bargh K., Templeton D., Medical Microbiology & Infectious Diseases, Global Health, Infectious diseases, APH - Aging & Later Life, AII - Infectious diseases, APH - Global Health, Graduate School, APH - Digital Health, APH - Personalized Medicine, Bohlius, Julia, Cohere In, Eurocoord, Castagna, Antonella, Rohner, E, Butikofer, L, Schmidlin, K, Sengayi, M, Maskew, M, Giddy, J, Garone, D, Moore, R, D'Souza, G, Goedert, J, Achenbach, C, Gill, M, Kitahata, M, Patel, P, Silverberg, M, Castilho, J, Mcgowan, C, Chen, Y, Law, M, Taylor, N, Paparizos, V, Bonnet, F, Verbon, A, Fatkenheuer, G, Post, F, Sabin, C, Mocroft, A, Le Moing, V, Dronda, F, Obel, N, Grabar, S, Spagnuolo, V, Antinori, A, Quiros-Roldan, E, Mussini, C, Miro, J, Meyer, L, Hasse, B, Konopnicki, D, Roca, B, Barger, D, Raben, D, Clifford, G, Franceschi, S, Brockmeyer, N, Chakraborty, R, Egger, M, Bohlius, J, Judd, A, Zangerle, R, Touloumi, G, Warszawski, J, Dabis, F, Krause, M, Ghosn, J, Leport, C, Wittkop, L, Reiss, P, Wit, F, Prins, M, Bucher, H, Gibb, D, Del Amo, J, Thorne, C, Kirk, O, Stephan, C, Perez-Hoyos, S, Hamouda, O, Bartmeyer, B, Chkhartishvili, N, Noguera-Julian, A, Monforte, A, Prieto, L, Conejo, P, Soriano-Arandes, A, Battegay, M, Kouyos, R, Tookey, P, Casabona, J, Castagna, A, Konopnick, D, Goetghebuer, T, Sonnerborg, A, Teira, R, Garrido, M, Haerry, D, De Wit, S, Costagliola, D, D'Arminio-Monforte, A, Chene, G, Schwimmer, C, Termote, M, Campbell, M, Frederiksen, C, Friis-Moller, N, Kjaer, J, Brandt, R, Berenguer, J, Bouteloup, V, Cozzi-Lepri, A, Davies, M, Dorrucci, M, Dunn, D, Furrer, H, Guiguet, M, Lambotte, O, Leroy, V, Lodi, S, Matheron, S, Monge, S, Nakagawa, F, Paredes, R, Phillips, A, Puoti, M, Schomaker, M, Smit, C, Sterne, J, Thiebaut, R, Torti, C, Van Der Valk, M, Tanser, F, Vinikoor, M, Macete, E, Wood, R, Stinson, K, Fatti, G, Phiri, S, Chimbetete, C, Malisita, K, Eley, B, Fritz, C, Hobbins, M, Kamenova, K, Fox, M, Prozesky, H, Technau, K, Sawry, S, Benson, C, Bosch, R, Kirk, G, Boswell, S, Mayer, K, Grasso, C, Hogg, R, Harrigan, P, Montaner, J, Yip, B, Zhu, J, Salters, K, Gabler, K, Buchacz, K, Brooks, J, Gebo, K, Carey, J, Rodriguez, B, Horberg, M, Thorne, J, Rabkin, C, Margolick, J, Jacobson, L, Klein, M, Rourke, S, Rachlis, A, Cupido, P, Hunter-Mellado, R, Mayor, A, Deeks, S, Martin, J, Saag, M, Mugavero, M, Willig, J, Eron, J, Napravnik, S, Crane, H, Drozd, D, Haas, D, Rebeiro, P, Turner, M, Bebawy, S, Rogers, B, Justice, A, Dubrow, R, Fiellin, D, Gange, S, Anastos, K, Althoff, K, Mckaig, R, Freeman, A, Lent, C, Van Rompaey, S, Morton, L, Mcreynolds, J, Lober, W, Abraham, A, Lau, B, Zhang, J, Jing, J, Modur, S, Wong, C, Hogan, B, Desir, F, Liu, B, You, B, Cahn, P, Cesar, C, Fink, V, Sued, O, Dell'Isola, E, Perez, H, Valiente, J, Yamamoto, C, Grinsztejn, B, Veloso, V, Luz, P, De Boni, R, Wagner, S, Friedman, R, Moreira, R, Pinto, J, Ferreira, F, Maia, M, De Menezes Succi, R, Machado, D, De Fatima Barbosa Gouvea, A, Wolff, M, Cortes, C, Rodriguez, M, Allendes, G, Pape, J, Rouzier, V, Marcelin, A, Perodin, C, Luque, M, Padgett, D, Madero, J, Ramirez, B, Belaunzaran, P, Vega, Y, Gotuzzo, E, Mejia, F, Carriquiry, G, Shepherd, B, Sterling, T, Jayathilake, K, Person, A, Giganti, M, Duda, S, Maruri, F, Vansell, H, Ly, P, Khol, V, Zhang, F, Zhao, H, Han, N, Lee, M, Li, P, Lam, W, Chan, Y, Kumarasamy, N, Saghayam, S, Ezhilarasi, C, Pujari, S, Joshi, K, Gaikwad, S, Chitalikar, A, Merati, T, Wirawan, D, Yuliana, F, Yunihastuti, E, Imran, D, Widhani, A, Tanuma, J, Oka, S, Nishijima, T, Choi, J, Na, S, Kim, J, Sim, B, Gani, Y, David, R, Kamarulzaman, A, Syed Omar, S, Ponnampalavanar, S, Azwa, I, Ditangco, R, Uy, E, Bantique, R, Wong, W, Ku, W, Wu, P, Ng, O, Lim, P, Lee, L, Ohnmar, P, Avihingsanon, A, Gatechompol, S, Phanuphak, P, Phadungphon, C, Kiertiburanakul, S, Sungkanuparph, S, Chumla, L, Sanmeema, N, Chaiwarith, R, Sirisanthana, T, Kotarathititum, W, Praparattanapan, J, Kantipong, P, Kambua, P, Ratanasuwan, W, Sriondee, R, Nguyen, K, Bui, H, Nguyen, D, Cuong, D, An, N, Luan, N, Sohn, A, Ross, J, Petersen, B, Cooper, D, Jiamsakul, A, Boettiger, D, Ellis, D, Bloch, M, Agrawal, S, Vincent, T, Allen, D, Smith, D, Rankin, A, Baker, D, Templeton, D, Jackson, E, Mccallum, K, Ryder, N, Sweeney, G, Carr, A, Macrae, K, Hesse, K, Finlayson, R, Gupta, S, Langton-Lockton, J, Shakeshaft, J, Brown, K, Idle, S, Arvela, N, Varma, R, Lu, H, Couldwell, D, Eswarappa, S, Furner, V, Cabrera, G, Fernando, S, Cogle, A, Lawrence, C, Mulhall, B, Boyd, M, Petoumenos, K, Puhr, R, Huang, R, Han, A, Gunathilake, M, Payne, R, O'Sullivan, M, Croydon, A, Russell, D, Cashman, C, Roberts, C, Sowden, D, Taing, K, Marshall, P, Orth, D, Youds, D, Rowling, D, Latch, N, Warzywoda, E, Dickson, B, Donohue, W, Edwards, S, Boyd, S, Roth, N, Lau, H, Read, T, Silvers, J, Zeng, W, Hoy, J, Watson, K, Bryant, M, Price, S, Woolley, I, Giles, M, Korman, T, Williams, J, Nolan, D, Allen, A, Guelfi, G, Mills, G, Wharry, C, Raymond, N, and Bargh, K

Subjects
Male, viruses, HIV Infections, Men who have sex with men, Cohort Studies, 0302 clinical medicine, Risk Factors, Antiretroviral therapy, Cohort study, HIV, Kaposi sarcoma, Adolescent, Adult, Anti-Retroviral Agents, CD4 Lymphocyte Count, Female, HIV-1, Humans, Middle Aged, Sarcoma, Kaposi, Viral Load, Young Adult, 030212 general & internal medicine, Articles and Commentaries, Incidence (epidemiology), Hazard ratio, virus diseases, Sarcoma, 3. Good health, Infectious Diseases, 030220 oncology & carcinogenesis, Cohort, Coinfection, Microbiology (medical), antiretroviral therapy, 610 Medicine & health, Kaposi, 03 medical and health sciences, SDG 3 - Good Health and Well-being, 360 Social problems & social services, medicine, cohort study, business.industry, medicine.disease, Confidence interval, business, Demography
Abstract

Background We compared Kaposi sarcoma (KS) risk in adults who started antiretroviral therapy (ART) across the Asia-Pacific, South Africa, Europe, Latin, and North America. Methods We included cohort data of human immunodeficiency virus (HIV)-positive adults who started ART after 1995 within the framework of 2 large collaborations of observational HIV cohorts. We present incidence rates and adjusted hazard ratios (aHRs). Results We included 208140 patients from 57 countries. Over a period of 1066572 person-years, 2046 KS cases were diagnosed. KS incidence rates per 100000 person-years were 52 in the Asia-Pacific and ranged between 180 and 280 in the other regions. KS risk was 5 times higher in South African women (aHR, 4.56; 95% confidence intervals [CI], 2.73-7.62) than in their European counterparts, and 2 times higher in South African men (2.21; 1.34-3.63). In Europe, Latin, and North America KS risk was 6 times higher in men who have sex with men (aHR, 5.95; 95% CI, 5.09-6.96) than in women. Comparing patients with current CD4 cell counts ≥700 cells/µL with those whose counts were

Published
2017

11. Evaluation of the North American Regional Reanalysis (NARR) precipitation fields in a topographically complex domain.

Author

Hunter, Cameron, Moore, R. D., and McKendry, Ian

Subjects
*METEOROLOGICAL precipitation, *PRECIPITATION gauges, *TOPOGRAPHY, *TERRITORIAL waters, *INFORMATION storage & retrieval systems
Abstract

The North American Regional Reanalysis (NARR) precipitation product was evaluated using station observations and catchment water yield in British Columbia (BC), Canada, at inter-annual, monthly, and daily time scales. A structural break occurred in 2003, associated with exclusion of Canadian precipitation gauge data from NARR's data assimilation process beginning in that year. The NARR product under-predicted precipitation in mountainous regions, over-predicted in the northern region of BC's Interior Plateau, and catchment-averaged NARR precipitation was less than observed water yield in coastal BC. The product was unable to reproduce even the seasonal pattern at three stations. This study highlights uncertainties associated with the NARR precipitation product, and presents a cautionary tale that is likely relevant not only to the application of NARR in BC, but may be relevant for other re-analysis products and other regions with complex topography and sparse station networks. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

22. Temporal Trends in Presentation and Survival for HIV-Associated Lymphoma in the Antiretroviral Therapy Era

Author

Gopal, S., primary, Patel, M. R., additional, Yanik, E. L., additional, Cole, S. R., additional, Achenbach, C. J., additional, Napravnik, S., additional, Burkholder, G. A., additional, Reid, E. G., additional, Rodriguez, B., additional, Deeks, S. G., additional, Mayer, K. H., additional, Moore, R. D., additional, Kitahata, M. M., additional, Eron, J. J., additional, and Richards, K. L., additional

Published
2013
Full Text
View/download PDF

25. Risk of End‐Stage Renal Disease in HIV‐Positive Potential Live Kidney Donors

Author

Muzaale, A. D., Althoff, K. N., Sperati, C. J., Abraham, A. G., Kucirka, L. M., Massie, A. B., Kitahata, M. M., Horberg, M. A., Justice, A. C., Fischer, M. J., Silverberg, M. J., Butt, A. A., Boswell, S. L., Rachlis, A. R., Mayor, A. M., Gill, M. J., Eron, J. J., Napravnik, S., Drozd, D. R., Martin, J. N., Bosch, R. J., Durand, C. M., Locke, J. E., Moore, R. D., Lucas, G. M., and Segev, D. L.

Abstract

New federal regulations allow HIV‐positive individuals to be live kidney donors; however, potential candidacy for donation is poorly understood given the increased risk of end‐stage renal disease (ESRD) associated with HIV infection. To better understand this risk, we compared the incidence of ESRDamong 41 968 HIV‐positive participants of North America AIDSCohort Collaboration on Research and Design followed for a median of 5 years with the incidence of ESRDamong comparable HIV‐negative participants of National Health and Nutrition Examination IIIfollowed for a median of 14 years. We used risk associations from multivariable Cox proportional hazards regression to derive cumulative incidence estimates for selected HIV‐positive scenarios (no history of diabetes, hypertension, AIDS, or hepatitis C viruscoinfection) and compared these estimates with those from similarly selected HIV‐negative scenarios. For 40‐year‐old HIV‐positive individuals with health characteristics that were similar to those of age‐matched kidney donors, viral load <400 copies/mL, and CD4+count ≥500 cells/μL, the 9‐year cumulative incidence of ESRDwas higher than that of their HIV‐negative peers, yet still low: 2.5 versus 1.1 per 10 000 among white women, 3.0 versus 1.3 per 10 000 among white men, 13.2 versus 3.6 per 10 000 among black women, and 15.8 versus 4.4 per 10 000 among black men. HIV‐positive individuals with no comorbidities and well‐controlled disease may be considered low‐risk kidney donor candidates. This North American study demonstrates that HIV‐positive individuals with no comorbidities and well‐controlled disease may be considered low‐risk live kidney donor candidates. See Steiner's editorial on page 1701.

Published
2017
Full Text
View/download PDF

34. Reply to Gupta

Author

Gallant, J. E., primary, Parish, M. A., additional, Keruly, J. C., additional, and Moore, R. D., additional

Published
2005
Full Text
View/download PDF

40. Community-Acquired Pneumonia

Author

Mundy, L M, primary, Auwaerter, P G, additional, Oldach, D, additional, Warner, M L, additional, Burton, A, additional, Vance, E, additional, Gaydos, C A, additional, Joseph, J M, additional, Gopalan, R, additional, Moore, R D, additional, Quinn, T C, additional, Charache, P, additional, and Bartlett, J G, additional

Published
1996
Full Text
View/download PDF

41. Reply

Author

Gallant, J. E., primary, Moore, R. D., additional, and Chaisson, R. E., additional

Published
1996
Full Text
View/download PDF

43. Reply

Author

Gallant, J. E., primary, Chaisson, R. E., additional, Keruly, J., additional, and Moore, R. D., additional

Published
1993
Full Text
View/download PDF

46. Can restrictions on reimbursement for anti-ulcer drugs decrease Medicaid pharmacy costs without increasing hospitalizations?

Author

Cromwell, David M., Bass, Eric B., Cromwell, D M, Bass, E B, Steinberg, E P, Yasui, Y, Ravich, W J, Hendrix, T R, McLeod, S F, and Moore, R D

Subjects
PEPTIC ulcer, ULCER treatment, HEALTH policy, MEDICAID, ECONOMIC impact, MEDICAL care cost statistics, COMPARATIVE studies, COST control, DECISION making, DRUG utilization, HOSPITAL care, GASTROINTESTINAL agents, MANAGEMENT, RESEARCH methodology, MEDICAL cooperation, REGRESSION analysis, RESEARCH, RESEARCH funding, HEALTH insurance reimbursement, EVALUATION research, ECONOMICS, THERAPEUTICS
Abstract

Objective: To examine the impact of a policy restricting reimbursement for Medicaid anti-ulcer drugs on anti-ulcer drug use and peptic-related hospitalizations.Data Sources/study Setting: In addition to U.S. Census Bureau data, all of the following from Florida: Medicaid anti-ulcer drug claims data, 1989-1993; Medicaid eligibility data, 1989-1993; and acute care nonfederal hospital discharge abstract data (Medicaid and non-Medicaid), 1989-1993.Study Design: In this observational study, a Poisson multiple regression model was used to compare changes, after policy implementation, in Medicaid reimbursement for prescription anti-ulcer drugs as well as hospitalization rates between pre- and post-implementation periods in Medicaid versus non-Medicaid patients hospitalized with peptic ulcer disease.Principal Findings: Following policy implementation, the rate of Medicaid reimbursement for anti-ulcer drugs decreased 33 percent (p < .001). No associated increase occurred in the rate of Medicaid peptic-related hospitalizations.Conclusions: Florida's policy restricting Medicaid reimbursement for anti-ulcer drugs was associated with a substantial reduction in outpatient anti-ulcer drug utilization without any significant increase in the rate of hospitalization for peptic-related conditions. [ABSTRACT FROM AUTHOR]

Published
1999

47. Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients.

Author

Maenza, Janine R., Keruly, Jeanne C., Moore, Richard D., Chaisson, Richard E., Merz, William G., Gallant, Joel E., Maenza, J R, Keruly, J C, Moore, R D, Chaisson, R E, Merz, W G, and Gallant, J E

Subjects
ANTIFUNGAL agents, CANDIDA, COMPARATIVE studies, DRUG resistance in microorganisms, ESOPHAGUS diseases, IMMUNOLOGICAL tolerance, RESEARCH methodology, MEDICAL cooperation, MICROBIAL sensitivity tests, RESEARCH, RESEARCH funding, THRUSH (Mouth disease), AIDS-related opportunistic infections, EVALUATION research, CASE-control method, FLUCONAZOLE, CD4 lymphocyte count, PHARMACODYNAMICS
Abstract

In a case-control study to identify risk factors for fluconazole-resistant oroesophageal candidiasis in human immunodeficiency virus-infected patients, 25 patients with clinical and in vitro fluconazole-resistant candidiasis were paired with controls who had treatment-responsive candidiasis and who had been observed for similar time periods. After their first episode of candidiasis, patients who later developed fluconazole resistance had more treated episodes than did matched controls (cases, 3.1; controls, 1.8; P = .004), lower median CD4 cell counts (11/mm3 vs. 71/mm/3; P = .004), and greater median durations of all antifungal therapy (419 vs. 118 days; P < .001) and of systemic azole therapy (272 vs. 14 days; P < .001). When paired with a second set of controls matched by CD4 cell count as well as first diagnosis of candidiasis, cases continued to show greater median exposure to azoles (272 vs. 88 days; P = .005). These data indicate that advanced immunosuppression and exposure to oral azoles are risk factors for the development of fluconazole resistance. [ABSTRACT FROM AUTHOR]

Published
1996

48. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration.

Author

Moore, Richard D., Lietman, Paul S., Smith, Craig R., Moore, R D, Lietman, P S, and Smith, C R

Subjects
BACTERIAL diseases, CLINICAL trials, COMPARATIVE studies, GENTAMICIN, GRAM-negative bacteria, RESEARCH methodology, MEDICAL cooperation, MICROBIAL sensitivity tests, RESEARCH, STATISTICAL sampling, EVALUATION research, TOBRAMYCIN, BLIND experiment, AMIKACIN, PHARMACODYNAMICS, THERAPEUTICS
Abstract

In an examination of the relationships among plasma aminoglycoside concentrations, the minimal inhibitory concentration (MIC) for the infecting organism, and therapeutic outcome, data were analyzed from 236 patients with gram-negative bacterial infections who were participants in four clinical trials of gentamicin, tobramycin, and amikacin. Clinical response to therapy occurred in 188 (80%) patients. Elevated maximal and mean peak aminoglycoside concentration/MIC ratios were strongly associated with clinical response (P less than .00001 and P less than .0001, respectively). A graded dose-response effect was found between an increasing maximal peak concentration/MIC ratio and clinical response. By logistic regression the peak concentration/MIC ratios were associated significantly with clinical response after adjustment for underlying severity of illness and other factors correlated with response. These results demonstrate that a high peak concentration relative to the MIC for the infecting organism is a major determinant of the clinical response to aminoglycoside therapy. [ABSTRACT FROM AUTHOR]

Published
1987
Full Text
View/download PDF

49. Risk factors for the development of auditory toxicity in patients receiving aminoglycosides.

Author

Moore, Richard D., Smith, Craig R., Lietman, Paul S., Moore, R D, Smith, C R, and Lietman, P S

Subjects
BODY temperature, CLINICAL trials, COMPARATIVE studies, GENTAMICIN, HEARING disorders, RESEARCH methodology, MEDICAL cooperation, PROBABILITY theory, RESEARCH, SEPSIS, STATISTICS, TIME, TOBRAMYCIN, EVALUATION research, RANDOMIZED controlled trials, RELATIVE medical risk, KANAMYCIN, AMIKACIN
Abstract

Risk factors for the development of auditory toxicity in patients receiving aminoglycosides were determined from the analysis of 135 patients enrolled in three prospective, randomized, double-blind clinical trials of gentamicin, tobramycin, and amikacin. Auditory toxicity, defined as a decrease in auditory acuity of greater than or equal to 15 dB, occurred in 30 patients (22.3%). Patients with auditory toxicity underwent therapy for a longer period, were more likely to be bacteremic, and had, on the average, a higher temperature (P less than 0.05). Using stepwise discriminant analysis, we selected these factors with liver dysfunction and the serum urea nitrogen:serum creatinine ratio in a function that accurately discriminates between toxic and nontoxic patients. Factors not adding significantly to the predictive accuracy of the equation were plasma aminoglycoside levels, aminoglycoside type, furosemide use, diabetes, age, sex, renal function, initial auditory acuity, hematocrit value, and shock. This analysis may be important both for determining the pathophysiology of auditory toxicity and for the prognostic stratification of patients receiving aminoglycosides in clinical trials. [ABSTRACT FROM AUTHOR]

Published
1984
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results